Osteoporosis.  2014 Dec;12(3):117-123. 10.0000/ost.2014.12.3.117.

Comparison of New Fractures after Treatment with Alendronate or Raloxifene in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation

• Seo JH
• Lee KY
• Kim KW
• Kim HH

• KMID: 2314149
• DOI: http://doi.org/10.0000/ost.2014.12.3.117

Abstract

BACKGROUND
S: The purpose of this study was to examine the incidence of new fractures after treatment with alendronate or raloxifene in patients with compression fractures treated with cement augmentation.
METHODS
140 patients with compression fracture treated with vertebroplasty or kyphoplasty between January 2007 and January 2013 were divided into 3 groups, an unmedicated group (n=31), an alendronate group (n=49), and a raloxifene group (n=60). The incidence of new fractures in 3 groups were investigated.
RESULTS
The incidence of new fractures was 29% (9 cases) in unmedicated group, 20% (10 case) in alendronate group, and 26% (16 case) in raloxifene group. Average period to new fracture was 16.2 months in alendronate group and 21.5 months in raloxifene group.
CONCLUSIONS
After treatment with alendronate or raloxifene, BMD increased and incidence of new fractures decreased in patients with osteoporotic compression fracture treated with vertebroplasty or kyphoplasty. Patients with alendronate showed numerical improvement in BMD and incidence of new fractures than raloxifene. But, incidence of new fractures in spine and other site showed no statisically significant.

Keyword

Osteoporosis; Compression fracture; Alendronate; Raloxifene

MeSH Terms

Alendronate*
Fractures, Compression*
Humans
Incidence
Kyphoplasty
Osteoporosis
Raloxifene Hydrochloride*
Spine
Vertebroplasty
Alendronate